REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2016

Jan 6, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2016-01-04

Reporting Person: Tessier-Lavigne Marc (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-04	Non-Qualified Stock Option (right to buy)	$520.01	A	9212.0	Acquired	2026-01-04	Common Stock (9212)	Direct

Footnotes

F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.